Evolus, Inc. (EOLS)
Market Cap | 719.52M |
Revenue (ttm) | 202.09M |
Net Income (ttm) | -61.69M |
Shares Out | 61.50M |
EPS (ttm) | -1.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 377,947 |
Open | 11.82 |
Previous Close | 11.72 |
Day's Range | 11.64 - 11.99 |
52-Week Range | 7.07 - 15.43 |
Beta | 1.45 |
Analysts | Strong Buy |
Price Target | 21.83 (+86.58%) |
Earnings Date | May 7, 2024 |
About EOLS
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. [Read more]
Full Company ProfileFinancial Performance
In 2023, Evolus's revenue was $202.09 million, an increase of 35.98% compared to the previous year's $148.62 million. Losses were -$61.69 million, -17.10% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price forecast is $21.83, which is an increase of 86.58% from the latest price.
News
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qu...
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of...
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its fina...
Evolus Announces Results from European Head-to-Head Filler Trial
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will provi...
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences.
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--To participate in the conference call, dial (877) 407-6184 or (201) 389-0877 or join the webcast on the Investor Relations page of the Evolus website.
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations.
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagheri...
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced it has entered into a definitive agre...
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results f...
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2...
Evolus to Participate in November Investor Conferences
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of it...
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox...
Evolus to Report Third Quarter 2023 Results
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus to Participate in September Conferences
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of it...
Evolus Announces Inducement Grants for New Chief Marketing Officer
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Compensat...
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today.
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus unveils fresh, new branding for its flagship neurotoxin product, Jeuveau.
Evolus Reports Second Quarter 2023 Results and Provides Business Update
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported financial results for the second quarter ended June 30, 2023 and provided a business update.
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year.
Evolus to Participate in Canaccord Genuity's 43rd Annual Growth Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that members of its management team will be participating in Canaccord Genuity's 43rd Annual Growth Conference in Boston.
Evolus to Report Second Quarter 2023 Results and Provide Business Update
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that it will report its second quarter 2023 financial results and provide a business update on Wednesday, August 2, 2023.
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. has commenced the commercial launch of Nuceiva® in Italy. The product is now available for direct order and delivery to customers.